Local Determinants of Thrombus Formation Following Sirolimus-Eluting Stent Implantation Assessed by Optical Coherence Tomography

Objectives We conducted this study to assess the prevalence and determinants of subclinical thrombus after sirolimus-eluting stent (SES) implantation. Background Angioscopic analyses have demonstrated the presence of thrombus is more common than the clinical incidence of SES thrombosis. Methods Fift...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JACC. Cardiovascular interventions 2009-05, Vol.2 (5), p.459-466
Hauptverfasser: Otake, Hiromasa, MD, Shite, Junya, MD, Ako, Junya, MD, Shinke, Toshiro, MD, Tanino, Yusuke, MD, Ogasawara, Daisuke, MD, Sawada, Takahiro, MD, Miyoshi, Naoki, MD, Kato, Hiroki, MD, Koo, Bon-Kwon, MD, Honda, Yasuhiro, MD, Fitzgerald, Peter J., MD, PhD, Hirata, Ken-ichi, MD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 466
container_issue 5
container_start_page 459
container_title JACC. Cardiovascular interventions
container_volume 2
creator Otake, Hiromasa, MD
Shite, Junya, MD
Ako, Junya, MD
Shinke, Toshiro, MD
Tanino, Yusuke, MD
Ogasawara, Daisuke, MD
Sawada, Takahiro, MD
Miyoshi, Naoki, MD
Kato, Hiroki, MD
Koo, Bon-Kwon, MD
Honda, Yasuhiro, MD
Fitzgerald, Peter J., MD, PhD
Hirata, Ken-ichi, MD
description Objectives We conducted this study to assess the prevalence and determinants of subclinical thrombus after sirolimus-eluting stent (SES) implantation. Background Angioscopic analyses have demonstrated the presence of thrombus is more common than the clinical incidence of SES thrombosis. Methods Fifty-three patients (53 lesions) underwent 6-month follow-up optical coherence tomography. A stent eccentricity index ([SEI] minimum/maximum stent diameter) was determined in each cross section. To evaluate unevenness of neointimal thickness, a neointimal unevenness score ([NUS] maximum neointimal thickness in the cross section/average neointimal thickness of the same cross section) was calculated for each cross section. Average SEI and NUS were calculated for each stent. Major adverse cardiac events were defined as a composite of death, myocardial infarction, and target vessel revascularization. Results Fourteen cases of thrombus (26%) were detected by optical coherence tomography (thrombus: n = 14 vs. nonthrombus: n = 39). The percentage of thrombus was associated with longer stents (36.4 ± 20.2 mm vs. 25.1 ± 9.8 mm; p = 0.008), a larger number of uncovered struts (17 ± 16 vs. 8 ± 11; p = 0.03), smaller average SEI (0.89 ± 0.04 vs. 0.92 ± 0.03; p = 0.001), and greater average NUS (2.22 ± 0.24 vs. 2.00 ± 0.33; p = 0.03). A significant relationship existed between average SEI and average NUS (p < 0.0001, R = 0.68), and between average SEI and the number of uncovered struts (p < 0.0006, R = 0.46). There was no significant difference in major adverse cardiac events during follow-up (median: 485 days, 7.1% vs. 12.8%; p > 0.99). Conclusions Longer stents and greater asymmetric stent expansion may be important determinants of thrombus formation after SES implantation. In this small cohort, the presence of thrombus did not increase the risk of major adverse cardiac events.
doi_str_mv 10.1016/j.jcin.2009.03.003
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733100404</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1936879809001927</els_id><sourcerecordid>733100404</sourcerecordid><originalsourceid>FETCH-LOGICAL-c559t-9ec764271a51cadc808b5b372549b238a097b8e64c26cb5bcf7da67f2aee68993</originalsourceid><addsrcrecordid>eNp9kcGL1DAUxoso7rr6D3iQ3jy1viRt0oAIy7irCwN72PEc0vR1J7VtxiRdmZt_uqkzIHgQAnkk3_cl7_ey7C2BkgDhH4ZyMHYuKYAsgZUA7Fl2SRrBC8Ghfp5qyXjRCNlcZK9CGAA4SEFfZhdEVpxVglxmv7bO6DH_jBH9ZGc9x5C7Pt_tvZvaJeS3zk86WjenahzdTzs_5g_Wu9FOSyhuxiX-OYk4x_xuOowp4CS_DgHT6vL2mN8fol1f2bg9epwN5js3uUevD_vj6-xFr8eAb877Vfbt9ma3-Vps77_cba63halrGQuJRvCKCqJrYnRnGmjaumWC1pVsKWt06qxtkFeGcpNuTC86zUVPNSJvpGRX2ftT7sG7HwuGqCYbDI7px-iWoARjBKCCKinpSWm8C8Fjrw7eTtofFQG1gleDWsGrFbwCphL4ZHp3jl_aCbu_ljPpJPh4EmBq8smiV8HYlUVnPZqoOmf_n__pH7sZ7bxS_Y5HDINb_JzwKaICVaAe1tGvkwcJQCQV7DdjRKwb</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733100404</pqid></control><display><type>article</type><title>Local Determinants of Thrombus Formation Following Sirolimus-Eluting Stent Implantation Assessed by Optical Coherence Tomography</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Otake, Hiromasa, MD ; Shite, Junya, MD ; Ako, Junya, MD ; Shinke, Toshiro, MD ; Tanino, Yusuke, MD ; Ogasawara, Daisuke, MD ; Sawada, Takahiro, MD ; Miyoshi, Naoki, MD ; Kato, Hiroki, MD ; Koo, Bon-Kwon, MD ; Honda, Yasuhiro, MD ; Fitzgerald, Peter J., MD, PhD ; Hirata, Ken-ichi, MD</creator><creatorcontrib>Otake, Hiromasa, MD ; Shite, Junya, MD ; Ako, Junya, MD ; Shinke, Toshiro, MD ; Tanino, Yusuke, MD ; Ogasawara, Daisuke, MD ; Sawada, Takahiro, MD ; Miyoshi, Naoki, MD ; Kato, Hiroki, MD ; Koo, Bon-Kwon, MD ; Honda, Yasuhiro, MD ; Fitzgerald, Peter J., MD, PhD ; Hirata, Ken-ichi, MD</creatorcontrib><description>Objectives We conducted this study to assess the prevalence and determinants of subclinical thrombus after sirolimus-eluting stent (SES) implantation. Background Angioscopic analyses have demonstrated the presence of thrombus is more common than the clinical incidence of SES thrombosis. Methods Fifty-three patients (53 lesions) underwent 6-month follow-up optical coherence tomography. A stent eccentricity index ([SEI] minimum/maximum stent diameter) was determined in each cross section. To evaluate unevenness of neointimal thickness, a neointimal unevenness score ([NUS] maximum neointimal thickness in the cross section/average neointimal thickness of the same cross section) was calculated for each cross section. Average SEI and NUS were calculated for each stent. Major adverse cardiac events were defined as a composite of death, myocardial infarction, and target vessel revascularization. Results Fourteen cases of thrombus (26%) were detected by optical coherence tomography (thrombus: n = 14 vs. nonthrombus: n = 39). The percentage of thrombus was associated with longer stents (36.4 ± 20.2 mm vs. 25.1 ± 9.8 mm; p = 0.008), a larger number of uncovered struts (17 ± 16 vs. 8 ± 11; p = 0.03), smaller average SEI (0.89 ± 0.04 vs. 0.92 ± 0.03; p = 0.001), and greater average NUS (2.22 ± 0.24 vs. 2.00 ± 0.33; p = 0.03). A significant relationship existed between average SEI and average NUS (p &lt; 0.0001, R = 0.68), and between average SEI and the number of uncovered struts (p &lt; 0.0006, R = 0.46). There was no significant difference in major adverse cardiac events during follow-up (median: 485 days, 7.1% vs. 12.8%; p &gt; 0.99). Conclusions Longer stents and greater asymmetric stent expansion may be important determinants of thrombus formation after SES implantation. In this small cohort, the presence of thrombus did not increase the risk of major adverse cardiac events.</description><identifier>ISSN: 1936-8798</identifier><identifier>EISSN: 1876-7605</identifier><identifier>DOI: 10.1016/j.jcin.2009.03.003</identifier><identifier>PMID: 19463471</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Angioplasty, Balloon, Coronary ; Aspirin - therapeutic use ; Cardiovascular ; Coronary Restenosis - etiology ; Coronary Restenosis - prevention &amp; control ; Coronary Thrombosis - diagnostic imaging ; Coronary Thrombosis - etiology ; Coronary Thrombosis - prevention &amp; control ; Drug-Eluting Stents ; Female ; Humans ; Immunosuppressive Agents - therapeutic use ; Japan ; Male ; Multivariate Analysis ; optical coherence tomography ; Platelet Aggregation Inhibitors - therapeutic use ; Prospective Studies ; Risk Assessment ; Risk Factors ; Sirolimus - administration &amp; dosage ; Sirolimus - therapeutic use ; sirolimus-eluting stents ; thrombus ; Ticlopidine - analogs &amp; derivatives ; Ticlopidine - therapeutic use ; Tomography, Optical Coherence ; Ultrasonography, Interventional</subject><ispartof>JACC. Cardiovascular interventions, 2009-05, Vol.2 (5), p.459-466</ispartof><rights>American College of Cardiology Foundation</rights><rights>2009 American College of Cardiology Foundation</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c559t-9ec764271a51cadc808b5b372549b238a097b8e64c26cb5bcf7da67f2aee68993</citedby><cites>FETCH-LOGICAL-c559t-9ec764271a51cadc808b5b372549b238a097b8e64c26cb5bcf7da67f2aee68993</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1936879809001927$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19463471$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Otake, Hiromasa, MD</creatorcontrib><creatorcontrib>Shite, Junya, MD</creatorcontrib><creatorcontrib>Ako, Junya, MD</creatorcontrib><creatorcontrib>Shinke, Toshiro, MD</creatorcontrib><creatorcontrib>Tanino, Yusuke, MD</creatorcontrib><creatorcontrib>Ogasawara, Daisuke, MD</creatorcontrib><creatorcontrib>Sawada, Takahiro, MD</creatorcontrib><creatorcontrib>Miyoshi, Naoki, MD</creatorcontrib><creatorcontrib>Kato, Hiroki, MD</creatorcontrib><creatorcontrib>Koo, Bon-Kwon, MD</creatorcontrib><creatorcontrib>Honda, Yasuhiro, MD</creatorcontrib><creatorcontrib>Fitzgerald, Peter J., MD, PhD</creatorcontrib><creatorcontrib>Hirata, Ken-ichi, MD</creatorcontrib><title>Local Determinants of Thrombus Formation Following Sirolimus-Eluting Stent Implantation Assessed by Optical Coherence Tomography</title><title>JACC. Cardiovascular interventions</title><addtitle>JACC Cardiovasc Interv</addtitle><description>Objectives We conducted this study to assess the prevalence and determinants of subclinical thrombus after sirolimus-eluting stent (SES) implantation. Background Angioscopic analyses have demonstrated the presence of thrombus is more common than the clinical incidence of SES thrombosis. Methods Fifty-three patients (53 lesions) underwent 6-month follow-up optical coherence tomography. A stent eccentricity index ([SEI] minimum/maximum stent diameter) was determined in each cross section. To evaluate unevenness of neointimal thickness, a neointimal unevenness score ([NUS] maximum neointimal thickness in the cross section/average neointimal thickness of the same cross section) was calculated for each cross section. Average SEI and NUS were calculated for each stent. Major adverse cardiac events were defined as a composite of death, myocardial infarction, and target vessel revascularization. Results Fourteen cases of thrombus (26%) were detected by optical coherence tomography (thrombus: n = 14 vs. nonthrombus: n = 39). The percentage of thrombus was associated with longer stents (36.4 ± 20.2 mm vs. 25.1 ± 9.8 mm; p = 0.008), a larger number of uncovered struts (17 ± 16 vs. 8 ± 11; p = 0.03), smaller average SEI (0.89 ± 0.04 vs. 0.92 ± 0.03; p = 0.001), and greater average NUS (2.22 ± 0.24 vs. 2.00 ± 0.33; p = 0.03). A significant relationship existed between average SEI and average NUS (p &lt; 0.0001, R = 0.68), and between average SEI and the number of uncovered struts (p &lt; 0.0006, R = 0.46). There was no significant difference in major adverse cardiac events during follow-up (median: 485 days, 7.1% vs. 12.8%; p &gt; 0.99). Conclusions Longer stents and greater asymmetric stent expansion may be important determinants of thrombus formation after SES implantation. In this small cohort, the presence of thrombus did not increase the risk of major adverse cardiac events.</description><subject>Aged</subject><subject>Angioplasty, Balloon, Coronary</subject><subject>Aspirin - therapeutic use</subject><subject>Cardiovascular</subject><subject>Coronary Restenosis - etiology</subject><subject>Coronary Restenosis - prevention &amp; control</subject><subject>Coronary Thrombosis - diagnostic imaging</subject><subject>Coronary Thrombosis - etiology</subject><subject>Coronary Thrombosis - prevention &amp; control</subject><subject>Drug-Eluting Stents</subject><subject>Female</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Japan</subject><subject>Male</subject><subject>Multivariate Analysis</subject><subject>optical coherence tomography</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Prospective Studies</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Sirolimus - administration &amp; dosage</subject><subject>Sirolimus - therapeutic use</subject><subject>sirolimus-eluting stents</subject><subject>thrombus</subject><subject>Ticlopidine - analogs &amp; derivatives</subject><subject>Ticlopidine - therapeutic use</subject><subject>Tomography, Optical Coherence</subject><subject>Ultrasonography, Interventional</subject><issn>1936-8798</issn><issn>1876-7605</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcGL1DAUxoso7rr6D3iQ3jy1viRt0oAIy7irCwN72PEc0vR1J7VtxiRdmZt_uqkzIHgQAnkk3_cl7_ey7C2BkgDhH4ZyMHYuKYAsgZUA7Fl2SRrBC8Ghfp5qyXjRCNlcZK9CGAA4SEFfZhdEVpxVglxmv7bO6DH_jBH9ZGc9x5C7Pt_tvZvaJeS3zk86WjenahzdTzs_5g_Wu9FOSyhuxiX-OYk4x_xuOowp4CS_DgHT6vL2mN8fol1f2bg9epwN5js3uUevD_vj6-xFr8eAb877Vfbt9ma3-Vps77_cba63halrGQuJRvCKCqJrYnRnGmjaumWC1pVsKWt06qxtkFeGcpNuTC86zUVPNSJvpGRX2ftT7sG7HwuGqCYbDI7px-iWoARjBKCCKinpSWm8C8Fjrw7eTtofFQG1gleDWsGrFbwCphL4ZHp3jl_aCbu_ljPpJPh4EmBq8smiV8HYlUVnPZqoOmf_n__pH7sZ7bxS_Y5HDINb_JzwKaICVaAe1tGvkwcJQCQV7DdjRKwb</recordid><startdate>20090501</startdate><enddate>20090501</enddate><creator>Otake, Hiromasa, MD</creator><creator>Shite, Junya, MD</creator><creator>Ako, Junya, MD</creator><creator>Shinke, Toshiro, MD</creator><creator>Tanino, Yusuke, MD</creator><creator>Ogasawara, Daisuke, MD</creator><creator>Sawada, Takahiro, MD</creator><creator>Miyoshi, Naoki, MD</creator><creator>Kato, Hiroki, MD</creator><creator>Koo, Bon-Kwon, MD</creator><creator>Honda, Yasuhiro, MD</creator><creator>Fitzgerald, Peter J., MD, PhD</creator><creator>Hirata, Ken-ichi, MD</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20090501</creationdate><title>Local Determinants of Thrombus Formation Following Sirolimus-Eluting Stent Implantation Assessed by Optical Coherence Tomography</title><author>Otake, Hiromasa, MD ; Shite, Junya, MD ; Ako, Junya, MD ; Shinke, Toshiro, MD ; Tanino, Yusuke, MD ; Ogasawara, Daisuke, MD ; Sawada, Takahiro, MD ; Miyoshi, Naoki, MD ; Kato, Hiroki, MD ; Koo, Bon-Kwon, MD ; Honda, Yasuhiro, MD ; Fitzgerald, Peter J., MD, PhD ; Hirata, Ken-ichi, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c559t-9ec764271a51cadc808b5b372549b238a097b8e64c26cb5bcf7da67f2aee68993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Aged</topic><topic>Angioplasty, Balloon, Coronary</topic><topic>Aspirin - therapeutic use</topic><topic>Cardiovascular</topic><topic>Coronary Restenosis - etiology</topic><topic>Coronary Restenosis - prevention &amp; control</topic><topic>Coronary Thrombosis - diagnostic imaging</topic><topic>Coronary Thrombosis - etiology</topic><topic>Coronary Thrombosis - prevention &amp; control</topic><topic>Drug-Eluting Stents</topic><topic>Female</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Japan</topic><topic>Male</topic><topic>Multivariate Analysis</topic><topic>optical coherence tomography</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Prospective Studies</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Sirolimus - administration &amp; dosage</topic><topic>Sirolimus - therapeutic use</topic><topic>sirolimus-eluting stents</topic><topic>thrombus</topic><topic>Ticlopidine - analogs &amp; derivatives</topic><topic>Ticlopidine - therapeutic use</topic><topic>Tomography, Optical Coherence</topic><topic>Ultrasonography, Interventional</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Otake, Hiromasa, MD</creatorcontrib><creatorcontrib>Shite, Junya, MD</creatorcontrib><creatorcontrib>Ako, Junya, MD</creatorcontrib><creatorcontrib>Shinke, Toshiro, MD</creatorcontrib><creatorcontrib>Tanino, Yusuke, MD</creatorcontrib><creatorcontrib>Ogasawara, Daisuke, MD</creatorcontrib><creatorcontrib>Sawada, Takahiro, MD</creatorcontrib><creatorcontrib>Miyoshi, Naoki, MD</creatorcontrib><creatorcontrib>Kato, Hiroki, MD</creatorcontrib><creatorcontrib>Koo, Bon-Kwon, MD</creatorcontrib><creatorcontrib>Honda, Yasuhiro, MD</creatorcontrib><creatorcontrib>Fitzgerald, Peter J., MD, PhD</creatorcontrib><creatorcontrib>Hirata, Ken-ichi, MD</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>JACC. Cardiovascular interventions</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Otake, Hiromasa, MD</au><au>Shite, Junya, MD</au><au>Ako, Junya, MD</au><au>Shinke, Toshiro, MD</au><au>Tanino, Yusuke, MD</au><au>Ogasawara, Daisuke, MD</au><au>Sawada, Takahiro, MD</au><au>Miyoshi, Naoki, MD</au><au>Kato, Hiroki, MD</au><au>Koo, Bon-Kwon, MD</au><au>Honda, Yasuhiro, MD</au><au>Fitzgerald, Peter J., MD, PhD</au><au>Hirata, Ken-ichi, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Local Determinants of Thrombus Formation Following Sirolimus-Eluting Stent Implantation Assessed by Optical Coherence Tomography</atitle><jtitle>JACC. Cardiovascular interventions</jtitle><addtitle>JACC Cardiovasc Interv</addtitle><date>2009-05-01</date><risdate>2009</risdate><volume>2</volume><issue>5</issue><spage>459</spage><epage>466</epage><pages>459-466</pages><issn>1936-8798</issn><eissn>1876-7605</eissn><abstract>Objectives We conducted this study to assess the prevalence and determinants of subclinical thrombus after sirolimus-eluting stent (SES) implantation. Background Angioscopic analyses have demonstrated the presence of thrombus is more common than the clinical incidence of SES thrombosis. Methods Fifty-three patients (53 lesions) underwent 6-month follow-up optical coherence tomography. A stent eccentricity index ([SEI] minimum/maximum stent diameter) was determined in each cross section. To evaluate unevenness of neointimal thickness, a neointimal unevenness score ([NUS] maximum neointimal thickness in the cross section/average neointimal thickness of the same cross section) was calculated for each cross section. Average SEI and NUS were calculated for each stent. Major adverse cardiac events were defined as a composite of death, myocardial infarction, and target vessel revascularization. Results Fourteen cases of thrombus (26%) were detected by optical coherence tomography (thrombus: n = 14 vs. nonthrombus: n = 39). The percentage of thrombus was associated with longer stents (36.4 ± 20.2 mm vs. 25.1 ± 9.8 mm; p = 0.008), a larger number of uncovered struts (17 ± 16 vs. 8 ± 11; p = 0.03), smaller average SEI (0.89 ± 0.04 vs. 0.92 ± 0.03; p = 0.001), and greater average NUS (2.22 ± 0.24 vs. 2.00 ± 0.33; p = 0.03). A significant relationship existed between average SEI and average NUS (p &lt; 0.0001, R = 0.68), and between average SEI and the number of uncovered struts (p &lt; 0.0006, R = 0.46). There was no significant difference in major adverse cardiac events during follow-up (median: 485 days, 7.1% vs. 12.8%; p &gt; 0.99). Conclusions Longer stents and greater asymmetric stent expansion may be important determinants of thrombus formation after SES implantation. In this small cohort, the presence of thrombus did not increase the risk of major adverse cardiac events.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>19463471</pmid><doi>10.1016/j.jcin.2009.03.003</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1936-8798
ispartof JACC. Cardiovascular interventions, 2009-05, Vol.2 (5), p.459-466
issn 1936-8798
1876-7605
language eng
recordid cdi_proquest_miscellaneous_733100404
source MEDLINE; Elsevier ScienceDirect Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Aged
Angioplasty, Balloon, Coronary
Aspirin - therapeutic use
Cardiovascular
Coronary Restenosis - etiology
Coronary Restenosis - prevention & control
Coronary Thrombosis - diagnostic imaging
Coronary Thrombosis - etiology
Coronary Thrombosis - prevention & control
Drug-Eluting Stents
Female
Humans
Immunosuppressive Agents - therapeutic use
Japan
Male
Multivariate Analysis
optical coherence tomography
Platelet Aggregation Inhibitors - therapeutic use
Prospective Studies
Risk Assessment
Risk Factors
Sirolimus - administration & dosage
Sirolimus - therapeutic use
sirolimus-eluting stents
thrombus
Ticlopidine - analogs & derivatives
Ticlopidine - therapeutic use
Tomography, Optical Coherence
Ultrasonography, Interventional
title Local Determinants of Thrombus Formation Following Sirolimus-Eluting Stent Implantation Assessed by Optical Coherence Tomography
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T13%3A58%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Local%20Determinants%20of%20Thrombus%20Formation%20Following%20Sirolimus-Eluting%20Stent%20Implantation%20Assessed%20by%20Optical%20Coherence%20Tomography&rft.jtitle=JACC.%20Cardiovascular%20interventions&rft.au=Otake,%20Hiromasa,%20MD&rft.date=2009-05-01&rft.volume=2&rft.issue=5&rft.spage=459&rft.epage=466&rft.pages=459-466&rft.issn=1936-8798&rft.eissn=1876-7605&rft_id=info:doi/10.1016/j.jcin.2009.03.003&rft_dat=%3Cproquest_cross%3E733100404%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733100404&rft_id=info:pmid/19463471&rft_els_id=1_s2_0_S1936879809001927&rfr_iscdi=true